<!--#yiv6968521870 _filtered #yiv6968521870 {font-family:Cambria;panose-1:2 4
5 3 5 4 6 3 2 4;} _filtered #yiv6968521870 {font-family:Calibri;panose-1:2 15 5
2 2 2 4 3 2 4;} _filtered #yiv6968521870 {font-family:Times-Roman;panose-1:0 0
0 0 0 0 0 0 0 0;}#yiv6968521870 #yiv6968521870 p.yiv6968521870MsoNormal,
#yiv6968521870 li.yiv6968521870MsoNormal, #yiv6968521870
div.yiv6968521870MsoNormal
{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Cambria",
"serif";}#yiv6968521870 a:link, #yiv6968521870 span.yiv6968521870MsoHyperlink
{color:blue;text-decoration:underline;}#yiv6968521870 a:visited, #yiv6968521870
span.yiv6968521870MsoHyperlinkFollowed
{color:purple;text-decoration:underline;}#yiv6968521870
span.yiv6968521870EmailStyle17 {font-family:"Calibri",
"sans-serif";color:windowtext;}#yiv6968521870 p.yiv6968521870BasicParagraph,
#yiv6968521870 li.yiv6968521870BasicParagraph, #yiv6968521870
div.yiv6968521870BasicParagraph
{margin:0cm;margin-bottom:.0001pt;line-height:120%;font-size:12.0pt;font-family:Times-Roman;color:black;}#yiv6968521870
p.yiv6968521870Sansinterligne1, #yiv6968521870
li.yiv6968521870Sansinterligne1, #yiv6968521870
div.yiv6968521870Sansinterligne1
{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri",
"sans-serif";}#yiv6968521870 MsoChpDefault {font-family:"Calibri",
"sans-serif";} _filtered #yiv6968521870 {margin:72.0pt 72.0pt 72.0pt
72.0pt;}#yiv6968521870 div.yiv6968521870WordSection1 {}-->PRESS STATEMENT
UNAIDS welcomes further evidence of the efficacy of antiretroviral medicines in
preventing new HIV infections GENEVA, 24 February 2015—UNAIDS strongly welcomes
results from scientific trials presented at the 2015 Conference on Retroviruses
and Opportunistic Infections (CROI), held in Seattle, United States of America.
Two studies demonstrate that the antiretroviral medicines tenofovir and
emtricitabine when used as pre-exposure prophylaxis (PrEP) are 86% effective in
preventing new HIV infections among men who have sex with men. A third study
showed 96% efficacy in preventing new HIV infections when the HIV-negative
person in a serodiscordant couple(where one partner is living with HIV and the
other is not)had access to PrEP and the HIV-positive partner had access to
antiretroviral therapy. “These new results are a significant breakthrough in
advancing efforts to provide effective HIV prevention options to men who have
sex with men and to serodiscordant couples,” said Michel Sidibé, Executive
Director of UNAIDS. “The results are timely and important and will advance
global efforts to end the AIDS epidemic by 2030.” The PROUD study in the United
Kingdom enrolled more than 500 men who have sex with men at higher risk of HIV
infection. Half of the participants were given a daily pill of tenofovir and
emtricitabine, the other half were deferred for one year before starting PrEP.
According to the results presented at CROI, the people taking a daily pill of
tenofovir and emtricitabine were 86% less likely to become infected with HIV
than the people in the deferred group. Results presented by the organizers of
the Franco-Canadian IPERGAY study also showed the significant efficacy of PrEP.
In the IPERGAY study some 450 men who have sex with men at higher risk of HIV
infection were enrolled in a trial in which half were asked to take four
tablets of tenofovir and emtricitabine, two before and two after sexual
intercourse; the other half were given a placebo According to the results
presented, the people in the group taking the active pill before and after sex
were 86% less likely to become infected with HIV. In both the studies the
trials were modified to offer active antiretroviral medicines to all
participants after interim analysis of the data showed a significantly positive
effect. ThePartners PrEP Demonstration Project enrolled more than 1000
serodiscordant couples in Uganda and Kenya. The HIV-positive partner in each
serodiscordant couple was offered antiretroviral therapy and the HIV-negative
partner was offered PrEP. A computer simulation model calculated the efficacy
of PrEP combined with early treatment to be 96%. The Partners PrEP
Demonstration Project suggests that the use of PrEP as a potential bridge in
serodiscordant couples—used while the HIV-positive person commences treatment
until such a time that the risk of transmitting the virus is minimized—is
highly effective in reducing new HIV infections. Another study in South
Africa, the FACTS 001 trial, showed that despite moderate adherence, with
50–60% of sexual exposures happening in the presence of gel, the use of 1%
tenofovir as a vaginal gel was not effective in preventing new HIV infections
among young women at higher risk of HIV infection. Despite disappointing
results the study does provide valuable information about the urgent need to
find new and effective HIV prevention options that work for young women.
UNAIDS warmly congratulates the researchers on completing four major studies of
HIV prevention approaches in the populations that are most in need of
prevention. For men who have sex with men at higher risk of HIV infection and
for serodiscordant couples, PrEP, offered as part of a package of HIV
prevention measures, is a highly effective additional HIV prevention option. To
advance efforts to end the AIDS epidemic by 2030, UNAIDS stresses the continued
need for a combination approach to HIV prevention that includes biomedical,
behaviour change and structural approaches. [END] Contact UNAIDS Geneva| Sophie
Barton-Knott | tel. +41 22 791 1697| [email protected] UNAIDS The Joint
United Nations Programme on HIV/AIDS (UNAIDS) leads and inspires the world to
achieve its shared vision of zero new HIV infections, zero discrimination and
zero AIDS-related deaths. UNAIDS unites the efforts of 11 UN
organizations—UNHCR, UNICEF, WFP, UNDP, UNFPA, UNODC, UN Women, ILO, UNESCO,
WHO and the World Bank—and works closely with global and national partners
towards ending the AIDS epidemic by 2030. Learn more at unaids.org and connect
with us on Facebook and Twitter.
--
Vous recevez ce message, car vous êtes abonné au groupe Google Groupes REMASTP.
Pour vous désabonner de ce groupe et ne plus recevoir d'e-mails le concernant,
envoyez un e-mail à l'adresse [email protected].
Pour envoyer un message à ce groupe, adressez un e-mail à
[email protected].
Visitez ce groupe à l'adresse http://groups.google.com/group/remastp .
Pour plus d'options, visitez le site https://groups.google.com/d/optout .
